GenMark Diagnostics Company Profile (NASDAQ:GNMK)

About GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Industry, Sector and Symbol:

Sector: Medical
Industry: Advanced Medical Equipment & Technology
Sub-Industry: N/A
Symbol: NASDAQ:GNMK
CUSIP: N/A
Web: www.genmarkdx.com

Capitalization:

Market Cap: $440.62 million
Outstanding Shares: 54,667,000

Average Prices:

50 Day Moving Avg: $9.46
200 Day Moving Avg: $11.45
52 Week Range: $8.00 - $13.67

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -11.68
P/E Growth: 0.15

Sales & Book Value:

Annual Revenue: $50.59 million
Price / Sales: 8.71
Book Value: $1.71 per share
Price / Book: 4.71

Profitability:

EBITDA: ($49,930,000.00)
Net Margins: -111.96%
Return on Equity: -109.89%
Return on Assets: -60.26%

Debt:

Debt-to-Equity Ratio: 0.16%
Current Ratio: 3.60%
Quick Ratio: 3.39%

Misc:

Average Volume: 424,153 shs.
Beta: 0.91
Short Ratio: 24.58

Frequently Asked Questions for GenMark Diagnostics (NASDAQ:GNMK)

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc. (NASDAQ:GNMK) issued its earnings results on Tuesday, August, 1st. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.05. The company earned $12.36 million during the quarter, compared to analysts' expectations of $12.44 million. GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.30) earnings per share. View GenMark Diagnostics' Earnings History.

When will GenMark Diagnostics make its next earnings announcement?

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for GenMark Diagnostics.

Where is GenMark Diagnostics' stock going? Where will GenMark Diagnostics' stock price be in 2017?

5 brokers have issued 12-month target prices for GenMark Diagnostics' stock. Their forecasts range from $13.00 to $17.00. On average, they expect GenMark Diagnostics' stock price to reach $14.40 in the next year. View Analyst Ratings for GenMark Diagnostics.

Who are some of GenMark Diagnostics' key competitors?

Some companies that are related to GenMark Diagnostics include LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), ViewRay (VRAY), Accuray Incorporated (ARAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Harvard Bioscience (HBIO), Neovasc (NVCN), IRIDEX Corporation (IRIX), Viveve Medical (VIVE), Edap Tms S.A. (EDAP), Presbia PLC (LENS), Fulgent Genetic (FLGT), Electromed (ELMD), Biolase (BIOL), Digirad Corporation (DRAD) and Invivo Therapeutics Holdings Corp (NVIV).

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:

James Charles Fox Ph.D., Independent Chairman of the Board
Hany Massarany, President, Chief Executive Officer, Director
Scott Mendel, Chief Financial Officer
Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development, Chief Scientific Officer
Eric Stier, Senior Vice President, General Counsel, Secretary
Jennifer Anne Williams, Senior Vice President - Human Resources
Michael W Gleeson, Senior Vice President, North American Commercial Operations
Michael S Kagnoff, Director
Daryl Jay Faulkner, Independent Director
Lisa M. Giles, Independent Director

How do I buy GenMark Diagnostics stock?

Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GenMark Diagnostics stock can currently be purchased for approximately $8.06.

MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		257 (Vote Outperform)
Underperform Votes:		103 (Vote Underperform)
Total Votes:		360

MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for GenMark Diagnostics (NASDAQ:GNMK) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	5 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$14.40 (78.66% upside)

Consensus Price Target History for GenMark Diagnostics (NASDAQ:GNMK)

Analysts' Ratings History for GenMark Diagnostics (NASDAQ:GNMK)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/4/2017	Needham & Company LLC	Reiterated Rating	Buy	$15.00	Medium
9/27/2017	Canaccord Genuity	Reiterated Rating	Buy		Medium
9/18/2017	Bank of America Corporation	Initiated Coverage	Buy -> Buy	$13.00	High
8/31/2017	BTIG Research	Reiterated Rating	Buy -> Buy	$13.00	High
8/2/2017	Cowen and Company	Reiterated Rating	Outperform	$17.00	High
7/29/2016	J P Morgan Chase & Co	Boost Price Target	Overweight	$10.00 -> $13.00	N/A
2/26/2016	Raymond James Financial, Inc.	Lower Price Target	Outperform	$9.00 -> $7.25	N/A

(Data available from 10/18/2015 forward)

Earnings History for GenMark Diagnostics (NASDAQ:GNMK)

Earnings by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Earnings History by Quarter for GenMark Diagnostics (NASDAQ GNMK)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/1/2017		($0.26)					N/A
8/1/2017	Q2 2017	($0.32)	($0.37)	$12.44 million	$12.36 million	View	Listen
5/2/2017	Q1 2017	($0.28)	($0.30)	$12.55 million	$12.54 million	View	Listen
2/28/2017	Q416	($0.27)	($0.27)	$15.03 million	$14.90 million	View	Listen
11/3/2016	Q316	($0.31)	($0.27)	$10.36 million	$10.80 million	View	N/A
7/28/2016	Q216	($0.33)	($0.30)	$9.62 million	$12.50 million	View	Listen
5/3/2016	Q116	($0.29)	($0.30)	$10.67 million	$11.06 million	View	N/A
2/23/2016	Q415	($0.27)	($0.21)	$12.34 million	$13.20 million	View	Listen
10/27/2015	Q315	($0.31)	($0.27)	$8.24 million	$8.80 million	View	Listen
8/6/2015	Q215	($0.31)	($0.29)	$7.59 million	$7.65 million	View	N/A
5/5/2015	Q115	($0.24)	($0.24)	$10.10 million	$10.10 million	View	N/A
2/24/2015	Q414	($0.28)	($0.21)	$9.83 million	$9.83 million	View	N/A
10/30/2014	Q314	($0.32)	($0.23)	$5.80 million	$6.30 million	View	N/A
8/11/2014	Q214	($0.29)	($0.27)	$4.79 million	$6.55 million	View	N/A
5/6/2014	Q114	($0.25)	($0.21)	$6.40 million	$7.91 million	View	N/A
3/11/2014	Q413	($0.22)	($0.21)	$6.06 million	$6.45 million	View	N/A
11/12/2013	Q313	($0.27)	($0.24)	$4.60 million	$4.64 million	View	Listen
8/7/2013	Q2 2013	($0.26)	($0.25)	$5.05 million	$5.20 million	View	N/A
5/8/2013	Q1 2013	($0.17)	($0.13)	$9.53 million	$11.10 million	View	N/A
11/10/2011		($0.32)	($0.31)			View	N/A
8/5/2011		($0.45)	($0.39)			View	N/A
5/9/2011		($0.49)	($0.56)			View	N/A
3/3/2011		($0.52)	($0.30)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for GenMark Diagnostics (NASDAQ:GNMK)

Current Year EPS Consensus Estimate: $-1.07 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS

Dividend History for GenMark Diagnostics (NASDAQ:GNMK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for GenMark Diagnostics (NASDAQ:GNMK)

Insider Ownership Percentage: 7.50%

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Insider Trades by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
10/2/2017	Eric Stier	SVP	Sell	2,750	$9.60	$26,400.00
9/15/2017	Jennifer Anne Williams	SVP	Sell	38,681	$9.08	$351,223.48
9/11/2017	Michael Kagnoff	Director	Buy	2,500	$9.15	$22,875.00
9/5/2017	Eric Stier	SVP	Sell	311	$9.75	$3,032.25
8/21/2017	Hany Massarany	Insider	Sell	8,311	$9.45	$78,538.95
8/21/2017	Michael Gleeson	SVP	Sell	1,933	$9.45	$18,266.85
8/21/2017	Scott Mendel	CFO	Sell	2,898	$9.45	$27,386.10
8/15/2017	Scott Mendel	CFO	Sell	1,752	$10.16	$17,800.32
8/2/2017	Hany Massarany	Insider	Sell	1,629	$10.33	$16,827.57
8/2/2017	Jon Faiz Kayyem	SVP	Sell	138	$10.33	$1,425.54
8/2/2017	Scott Mendel	CFO	Sell	333	$10.33	$3,439.89
6/2/2017	Michael Gleeson	SVP	Sell	357	$12.89	$4,601.73
5/19/2017	Hany Massarany	Insider	Sell	8,239	$12.89	$106,200.71
5/19/2017	Michael Gleeson	SVP	Sell	1,916	$12.89	$24,697.24
5/19/2017	Scott Mendel	CFO	Sell	2,135	$12.89	$27,520.15
5/16/2017	Scott Mendel	CFO	Sell	1,268	$13.43	$17,029.24
5/2/2017	Eric Stier	SVP	Sell	362	$13.34	$4,829.08
5/2/2017	Hany Massarany	Insider	Sell	1,571	$13.34	$20,957.14
5/2/2017	Scott Mendel	CFO	Sell	232	$13.34	$3,094.88
3/3/2017	Michael Gleeson	SVP	Sell	353	$12.29	$4,338.37
2/21/2017	Hany Massarany	Insider	Sell	33,537	$10.08	$338,052.96
2/21/2017	Jon Faiz Kayyem	SVP	Sell	5,250	$10.08	$52,920.00
2/21/2017	Scott Mendel	CFO	Sell	8,595	$10.08	$86,637.60
2/2/2017	Hany Massarany	Insider	Sell	1,142	$11.58	$13,224.36
2/2/2017	Jennifer Anne Williams	SVP	Sell	332	$11.58	$3,844.56
2/2/2017	Scott Mendel	CFO	Sell	235	$11.58	$2,721.30
1/19/2017	Hany Massarany	Insider	Sell	27,124	$12.47	$338,236.28
1/19/2017	Michael Gleeson	SVP	Sell	9,569	$12.47	$119,325.43
1/19/2017	Scott Mendel	CFO	Sell	9,098	$12.47	$113,452.06
12/5/2016	Jennifer Anne Williams	SVP	Sell	336	$11.31	$3,800.16
12/2/2016	Michael Gleeson	SVP	Sell	357	$11.30	$4,034.10
11/22/2016	Michael Kagnoff	Director	Buy	2,000	$11.80	$23,600.00
11/14/2016	Michael Kagnoff	Director	Buy	2,000	$12.50	$25,000.00
11/2/2016	Hany Massarany	Insider	Sell	1,148	$10.30	$11,824.40
11/2/2016	Michael Gleeson	SVP	Sell	400	$10.30	$4,120.00
9/7/2016	Hany Massarany	Insider	Sell	1,186	$8.69	$10,306.34
9/7/2016	Jennifer Anne Williams	SVP	Sell	523	$8.69	$4,544.87
9/2/2016	Jon Faiz Kayyem	SVP	Sell	133	$8.62	$1,146.46
8/29/2016	Jennifer Anne Williams	SVP	Sell	24,172	$8.63	$208,604.36
8/22/2016	Michael Gleeson	SVP	Sell	7,500	$9.00	$67,500.00
8/12/2016	Lisa M Giles	Director	Buy	823	$9.40	$7,736.20
8/2/2016	Eric Stier	SVP	Sell	367	$9.88	$3,625.96
8/2/2016	Hany Massarany	Insider	Sell	1,147	$9.88	$11,332.36
6/7/2016	Hany Massarany	CEO	Sell	1,188	$8.98	$10,668.24
6/7/2016	Michael Gleeson	SVP	Sell	868	$8.80	$7,638.40
6/3/2016	Ingo Chakravarty	SVP	Sell	184	$8.53	$1,569.52
5/9/2016	Ingo Chakravarty	SVP	Sell	582	$5.42	$3,154.44
5/2/2016	Eric Stier	SVP	Sell	363	$5.79	$2,101.77
5/2/2016	Hany Massarany	CEO	Sell	1,160	$5.79	$6,716.40
3/10/2016	Michael Kagnoff	Director	Buy	2,500	$4.90	$12,250.00
3/7/2016	Hany Massarany	CEO	Sell	1,193	$5.76	$6,871.68
3/7/2016	Michael Gleeson	SVP	Sell	559	$5.76	$3,219.84
3/2/2016	Eric Stier	SVP	Sell	365	$4.87	$1,777.55
2/9/2016	Ingo Chakravarty	SVP	Sell	697	$5.04	$3,512.88
2/3/2016	Hany Massarany	CEO	Sell	9,173	$4.99	$45,773.27
2/3/2016	Michael Gleeson	SVP	Sell	3,083	$4.99	$15,384.17
1/21/2016	Hany Massarany	CEO	Sell	648	$6.80	$4,406.40
1/21/2016	Michael Gleeson	SVP	Sell	227	$6.80	$1,543.60
12/8/2015	Eric Stier	SVP	Sell	240	$7.26	$1,742.40
12/8/2015	Hany Massarany	CEO	Sell	1,735	$7.26	$12,596.10
12/3/2015	Hany Massarany	CEO	Sell	3,571	$7.71	$27,532.41
12/3/2015	Michael Gleeson	SVP	Sell	1,664	$7.62	$12,679.68
11/3/2015	Lisa M Giles	Director	Buy	4,000	$6.60	$26,400.00
10/30/2015	Michael Kagnoff	Director	Buy	5,000	$6.70	$33,500.00
10/30/2015	Scott Mendel	CFO	Buy	10,000	$6.47	$64,700.00
10/29/2015	Daryl Faulkner	Director	Buy	4,000	$7.33	$29,320.00
9/15/2015	Jennifer Anne Williams	SVP	Sell	14,245	$9.98	$142,165.10
9/14/2015	Jennifer Anne Williams	SVP	Sell	9,245	$10.00	$92,450.00
9/11/2015	Hany Massarany	CEO	Sell	1,683	$9.64	$16,224.12
9/11/2015	Jennifer Anne Williams	SVP	Sell	18,280	$9.99	$182,617.20
9/4/2015	Jennifer Anne Williams	SVP	Sell	1,867	$9.59	$17,904.53
9/2/2015	Hany Massarany	CEO	Sell	3,865	$9.62	$37,181.30
8/24/2015	Scott Mendel	CFO	Buy	10,000	$9.10	$91,000.00
6/16/2015	Hany Massarany	CEO	Sell	1,698	$9.12	$15,485.76
6/4/2015	Michael Gleeson	SVP	Sell	1,595	$9.55	$15,232.25
6/3/2015	Hany Massarany	CEO	Sell	3,486	$9.47	$33,012.42
4/9/2015	Hany Massarany	CEO	Sell	5,942	$11.52	$68,451.84
3/13/2015	Jennifer Anne Williams	SVP	Sell	30,000	$12.56	$376,800.00
3/11/2015	Hany Massarany	CEO	Sell	28,110	$11.88	$333,946.80
3/11/2015	Jeffrey Alan Hawkins	SVP	Sell	6,832	$12.01	$82,052.32
3/10/2015	Jennifer Anne Williams	SVP	Sell	722	$11.83	$8,541.26
3/10/2015	Michael Kagnoff	Director	Buy	5,000	$11.84	$59,200.00
3/9/2015	Ingo Chakravarty	SVP	Sell	3,310	$12.06	$39,918.60
1/22/2015	Hany Massarany	CEO	Sell	5,982	$12.88	$77,048.16
1/7/2015	Hany Massarany	CEO	Sell	4,858	$13.00	$63,154.00
12/16/2014	Kevin C Oboyle	Director	Sell	291	$12.40	$3,608.40
12/15/2014	Eric Stier	SVP	Sell	235	$12.51	$2,939.85
12/15/2014	Hany Massarany	CEO	Sell	1,700	$12.51	$21,267.00
12/4/2014	Hany Massarany	CEO	Sell	3,300	$12.06	$39,798.00
12/4/2014	Jeffrey Alan Hawkins	SVP	Sell	1,350	$12.06	$16,281.00
10/31/2014	Jon Faiz Kayyem	SVP	Sell	6,000	$11.01	$66,060.00
10/8/2014	Hany Massarany	CEO	Sell	5,804	$9.00	$52,236.00
10/7/2014	Michael Gleeson	SVP	Sell	55	$9.10	$500.50
9/12/2014	Hany Massarany	CEO	Sell	1,678	$9.86	$16,545.08
9/5/2014	Hany Massarany	CEO	Sell	3,795	$10.04	$38,101.80
9/5/2014	Michael Gleeson	SVP	Sell	1,833	$10.04	$18,403.32
8/7/2014	Michael Gleeson	SVP	Sell	52	$11.15	$579.80
7/1/2014	Jon Faiz Kayyem	SVP	Sell	6,000	$13.60	$81,600.00
6/11/2014	Hany Massarany	CEO	Sell	1,115	$11.64	$12,978.60
6/5/2014	Jon Faiz Kayyem	SVP	Sell	1,483	$10.69	$15,853.27
6/3/2014	Hany Massarany	CEO	Sell	2,700	$10.67	$28,809.00
5/29/2014	Kevin C Oboyle	Director	Sell	1,603	$10.98	$17,600.94
5/28/2014	Jon Faiz Kayyem	SVP	Sell	6,000	$11.06	$66,360.00
5/8/2014	Richard Slansky	CFO	Sell	2,302	$9.26	$21,316.52
4/9/2014	Hany Massarany	CEO	Sell	3,985	$9.87	$39,331.95
3/26/2014	Jennifer Anne Williams	SVP	Sell	30,195	$9.97	$301,044.15
3/5/2014	Jon Faiz Kayyem	SVP	Sell	7,355	$12.46	$91,643.30
1/16/2014	Jon Faiz Kayyem	SVP	Sell	50,000	$14.05	$702,500.00
1/7/2014	Hany Massarany	CEO	Sell	4,698	$13.31	$62,530.38
12/6/2013	Michael Gleeson	SVP	Sell	2,211	$11.14	$24,630.54
12/4/2013	Hany Massarany	CEO	Sell	3,968	$11.14	$44,203.52
10/9/2013	Hany Massarany	CEO	Sell	3,925	$12.05	$47,296.25
10/1/2013	Jon Faiz Kayyem	SVP	Sell	6,000	$12.14	$72,840.00
9/4/2013	Jeffrey Alan Hawkins	SVP	Sell	1,890	$11.60	$21,924.00
9/3/2013	Hany Massarany	CEO	Sell	2,354	$11.60	$27,306.40
9/3/2013	Jon Faiz Kayyem	SVP	Sell	1,545	$11.60	$17,922.00
8/20/2013	Jon Faiz Kayyem	SVP	Sell	1,310	$10.15	$13,296.50
7/1/2013	Jon Faiz Kayyem	SVP	Sell	6,000	$10.40	$62,400.00

(Data available from 1/1/2013 forward)

Headline Trends for GenMark Diagnostics (NASDAQ:GNMK) Latest Headlines for GenMark Diagnostics (NASDAQ:GNMK)

Source:

Date	Headline
	RSI Alert: GenMark Diagnostics (GNMK) Now Oversold www.thestreet.com - October 18 at 12:53 AM
	ETFs with exposure to GenMark Diagnostics, Inc. : October 16, 2017 finance.yahoo.com - October 16 at 3:50 PM
	GenMark Diagnostics, Inc. (GNMK) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - October 15 at 9:28 AM
	Is GenMark Diagnostics Inc (GNMK) Undervalued? finance.yahoo.com - October 12 at 8:03 PM
	Critical Comparison: GenMark Diagnostics (GNMK) versus Its Peers www.americanbankingnews.com - October 12 at 12:28 AM
	Analyzing GenMark Diagnostics (GNMK) and Its Rivals www.americanbankingnews.com - October 9 at 8:28 PM
	GenMark Diagnostics' (GNMK) "Buy" Rating Reaffirmed at Needham & Company LLC www.americanbankingnews.com - October 8 at 5:26 PM
	Reviewing GenMark Diagnostics (GNMK) & Its Competitors www.americanbankingnews.com - October 7 at 12:14 PM
	ETFs with exposure to GenMark Diagnostics, Inc. : October 5, 2017 finance.yahoo.com - October 5 at 7:26 PM
	GenMark Diagnostics, Inc. (GNMK) SVP Eric Stier Sells 2,750 Shares www.americanbankingnews.com - October 4 at 9:08 PM
	GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 finance.yahoo.com - October 4 at 12:23 PM
	GenMark Diagnostics' (GNMK) Buy Rating Reiterated at Canaccord Genuity www.americanbankingnews.com - October 1 at 5:14 PM
	Today's Research Report Coverage on Medical Equipment Stocks -- AcelRx Pharma, GenMark Diagnostics, ViewRay, and Nevro www.bizjournals.com - September 25 at 10:33 AM
	GenMark Diagnostics, Inc. (GNMK) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - September 20 at 9:24 AM
	GenMark Diagnostics, Inc. (GNMK) Coverage Initiated at Bank of America Corporation www.americanbankingnews.com - September 18 at 11:32 PM
	Insider Selling: GenMark Diagnostics, Inc. (GNMK) SVP Sells 38,681 Shares of Stock www.americanbankingnews.com - September 15 at 10:46 PM
	GenMark Diagnostics, Inc. (GNMK) PT Lowered to $15.00 www.americanbankingnews.com - September 13 at 8:04 AM
	Comparing GenMark Diagnostics (GNMK) & Koninklijke Philips N.V. (PHG) www.americanbankingnews.com - September 12 at 4:28 PM
	GenMark Diagnostics, Inc. (GNMK) Director Purchases $22,875.00 in Stock www.americanbankingnews.com - September 11 at 10:20 PM
	GenMark Diagnostics, Inc. (GNMK) Earns Buy Rating from Analysts at BTIG Research www.americanbankingnews.com - August 31 at 7:46 AM
	GenMark Diagnostics, Inc. (GNMK) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - August 26 at 9:26 AM
	$14.61 Million in Sales Expected for GenMark Diagnostics, Inc. (GNMK) This Quarter www.americanbankingnews.com - August 25 at 3:44 AM
	Insider Selling: GenMark Diagnostics, Inc. (GNMK) SVP Sells 1,933 Shares of Stock www.americanbankingnews.com - August 23 at 4:44 PM
	GenMark Diagnostics, Inc. (GNMK) CFO Sells $27,386.10 in Stock www.americanbankingnews.com - August 23 at 4:44 PM
	Hany Massarany Sells 8,311 Shares of GenMark Diagnostics, Inc. (GNMK) Stock www.americanbankingnews.com - August 23 at 4:20 PM
	GenMark Diagnostics, Inc. (GNMK) CFO Sells $17,800.32 in Stock www.americanbankingnews.com - August 15 at 10:23 PM
	GenMark Diagnostics, Inc. – Value Analysis (NASDAQ:GNMK) : August 8, 2017 finance.yahoo.com - August 8 at 6:51 PM
	Analysts Anticipate GenMark Diagnostics, Inc. (GNMK) Will Post Quarterly Sales of $14.81 Million www.americanbankingnews.com - August 7 at 8:58 AM
	GenMark Diagnostics, Inc. (GNMK) Insider Sells $16,827.57 in Stock www.americanbankingnews.com - August 4 at 4:30 PM
	GenMark Diagnostics, Inc. (GNMK) Forecasted to Earn FY2017 Earnings of ($1.12) Per Share www.americanbankingnews.com - August 3 at 9:52 AM
	Edited Transcript of GNMK earnings conference call or presentation 1-Aug-17 12:30pm GMT finance.yahoo.com - August 2 at 3:56 PM
	GenMark Diagnostics, Inc. (NASDAQ:GNMK) Stock Rating Reaffirmed by Cowen and Company www.americanbankingnews.com - August 2 at 9:50 AM
	Mid-Day Market Update: Pitney Bowes Drops On Earnings Miss; Lumber Liquidators Shares Climb www.nasdaq.com - August 2 at 12:48 AM
	GenMark Reports Second Quarter 2017 Results finance.yahoo.com - August 1 at 7:44 PM
	GenMark Diagnostics reports 2Q loss finance.yahoo.com - August 1 at 7:44 PM
	GenMark Diagnostics, Inc. (NASDAQ:GNMK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS www.americanbankingnews.com - August 1 at 2:20 PM
	GenMark Diagnostics, Inc. (NASDAQ:GNMK) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - August 1 at 9:23 AM
	GenMark Diagnostics to Attend Canaccord Genuity’s 37th Annual Growth Conference finance.yahoo.com - July 31 at 6:44 PM
	GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : July 27, 2017 finance.yahoo.com - July 27 at 7:44 PM
	GenMark Diagnostics, Inc. (NASDAQ:GNMK) Expected to Announce Quarterly Sales of $12.61 Million www.americanbankingnews.com - July 16 at 8:58 AM
	Brokerages Expect GenMark Diagnostics, Inc. (GNMK) to Announce -$0.31 EPS www.americanbankingnews.com - July 14 at 1:24 PM
	GenMark Diagnostics, Inc. (NASDAQ:GNMK) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - July 7 at 8:55 AM
	Research Analysts Offer Predictions for GenMark Diagnostics, Inc.'s FY2018 Earnings (GNMK) www.americanbankingnews.com - July 3 at 9:41 AM
	GenMark Diagnostics (GNMK) Announces CE Mark for ePlex Blood Culture Identification Gram-Positive and Gram-Negative Panels www.streetinsider.com - June 29 at 11:08 PM
	GenMark Diagnostics (GNMK) Commences $65M Common Stock Offering www.streetinsider.com - June 14 at 11:56 AM
	GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel www.businesswire.com - April 21 at 5:27 PM
	Commit To Buy GenMark Diagnostics At $10, Earn 11.1% Annualized Using Options www.nasdaq.com - April 7 at 10:04 AM
	GENMARK DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report biz.yahoo.com - March 1 at 12:11 PM
	GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition biz.yahoo.com - March 1 at 12:11 PM
	GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results www.businesswire.com - February 28 at 5:40 PM